340B
-
340B, Affordable Care Act, Caught my eye, Employers, Inflation Reduction Act, Medicare Negotiation, Medicare Part D, ValueAMP is WAC — 10/24/25
Read more: AMP is WAC — 10/24/25This week, I felt like my brain experienced a “low memory” error. My capacity was maxed out trying to tackle a Python coding challenge—a task that exists in an entirely different universe than my usual work. It was a blend of excitement and absurdity. But being outside one’s comfort zone actually feels pretty relevant to…
-
340B, Caught my eye, DTC, Medicaid, Medicare Negotiation, Medicare Part D, Reference Pricing, State-based ReformAMP is WAC — 10/10/25
Read more: AMP is WAC — 10/10/25Going crazy? Or is it just a party of one? This past month as been brutal. My house has been a parade of plumbers and HVAC and electricians. Plus, visits to orthopedists and veterinarians and car mechanics. If the universe is trying to say something, all I’m hearing is that I’m scoring a ton of…
-
340B, Caught my eye, Drug shortages, Inflation Reduction Act, Medicaid, Medicare Negotiation, Medicare Part D, Orphan DrugsAMP is WAC — 9/26/25
Read more: AMP is WAC — 9/26/25Feeling Owl Right? No? As I look at my calendar, I’m feeling a little antsy about the week ahead. Everything is positive, even great, but it feels like a gauntlet. The other significant factor is the upcoming September 29th Most Favored Nation (MFN) deadline. This date marks 60 days since the seventeen letters went out…
-
340B, Affordable Care Act, Caught my eye, CMMI, Drug Prices, DTC, Employers, Medicare Advantage, Medicare Part D, Reference Pricing, Supply Chain, Utilization ManagementAMP is WAC — 9/12/25
Read more: AMP is WAC — 9/12/25On one hand, a busy week in the world of health policy. The quicksand of news in 2025 is real so I do my best to sidestep some news (MAHA report) to dive into the things that I think are important for my clients – including expected premium spikes, 340B rebate backlash and Medicare changes.…
-
340B, Caught my eye, Drug Prices, Generics, Medicare Part D, Medicare Transaction Facilitator, Orphan Drugs, Reference Pricing, VaccinesAMP is WAC — 09/04/25
Read more: AMP is WAC — 09/04/25A Monday off is always a double win, longer weekend and shorter week. Caught My Eye Made me Laugh. 340B can be funny. Go PhRMA. Zebras, Not Unicorns. The Food and Drug Administration announced a new rare disease approval framework. While it acknowledges the challenge of rare disease, it is unclear if the new framework…
-
AMP is WAC — 8/29/25
Read more: AMP is WAC — 8/29/25It felt like a relatively quiet week. Or did I just completely jinx today? Caught my Eye Ask Me Anything. FAQs released on the 340B Model Pilot program. This is the program where manufacturers with 2026 Medicare negotiated drugs can move to a rebate program for 340B for the negotiated drugs. Manufacturers that submit plans…
-
340B, Alzheimer’s, Caught my eye, Drug Prices, Medicare Advantage, Medicare Negotiation, Medicare Part D, Medicare Transaction Facilitator, Reference PricingAMP is WAC — 08/01/25
Read more: AMP is WAC — 08/01/25Rumor has it that the weather will be cooler in the DC-area this weekend and I am giddy. Outside time sounds great – a hike, a cocktail on the patio, maybe getting the friend group together to start planning the next ski trip… hope you get a chance to dream big too. Caught my…
-
340B, Caught my eye, Drug shortages, Pharmacy Benefit Managers, Supply Chain, Utilization ManagementAMP is WAC — 7/25/25
Read more: AMP is WAC — 7/25/25Next week we’ll have our first glimpse of the Medicare Part D premiums for 2026; I expect them to be pretty awful. The Part D redesign shifted additional liability onto plans without changing enough of the premium calculation. Some articles next week will say it is unintended consequence; I think it is an intended one…
-
AMP is WAC — 7/18/25
Read more: AMP is WAC — 7/18/25I have a case of existential dread, and yet the world keeps spinning so let’s do this… Caught my Eye More Cowbell. Late last year I put out a report on biosimilars and it called out how the Inflation Reduction Act could hurt innovation and savings for biosimilars. Here is a report from Matrix Global…
-
AMP is WAC — 7/10/25
Read more: AMP is WAC — 7/10/25Last Saturday I was in the customs line in Amsterdam and the agent smirked and said, “Big Beautiful Bill, huh?” I wanted to say something, but I was mostly impressed that he was following U.S. news more closely than a lot of Americans. Caught my Eye 340No. IQVIA released a study looking at the use…
Latest news
- AMP is WAC — 3/6/26
- AMP is WAC — 02/27/26
- AMP is WAC — 2/20/26
- AMP is WAC — 2/13/26
- AMP is WAC — 2/6/26
Categories
- 340B (62)
- Affordable Care Act (21)
- Alzheimer's (10)
- Biosimilars (31)
- Caught my eye (101)
- Cell and Gene (5)
- Chevron Deference (2)
- CMMI (26)
- Copay Accumulators (7)
- COVID (3)
- Drug Prices (55)
- Drug shortages (14)
- DTC (6)
- Employers (20)
- FDA (6)
- Generics (12)
- Health Equity (4)
- Healthcare Costs (39)
- Home Health (1)
- ICER (12)
- Importation (5)
- Inflation Reduction Act (67)
- Insulin (7)
- IP (3)
- Long term care (1)
- Medicaid (22)
- Medicare Advantage (27)
- Medicare Negotiation (68)
- Medicare Part D (76)
- Medicare Transaction Facilitator (5)
- Medicare Transaction Facilitator (12)
- Obesity (26)
- On the Horizon (1)
- Orphan Drugs (8)
- Pharmacy Benefit Managers (48)
- Preventative (5)
- Reference Pricing (26)
- State-based Reform (30)
- Supply Chain (7)
- Tariffs (1)
- Uncategorized (8)
- Utilization Management (11)
- Vaccines (9)
- Value (18)